Literature DB >> 27368915

Comparison of dosimetric parameters and acute toxicity of intensity-modulated and three-dimensional radiotherapy in patients with cervix carcinoma: A randomized prospective study.

A Naik1, O P Gurjar2, K L Gupta2, K Singh2, P Nag2, V Bhandari2.   

Abstract

PURPOSE: The use of intensity-modulated radiotherapy (IMRT) to treat cervix carcinoma has increased, however prospective randomized trials are still lacking. AIM: To compare the dosimetric parameters and associated acute toxicity in patients with cervix carcinoma treated with three-dimensional (3D) conformal radiotherapy and IMRT. PATIENTS AND METHODS: Forty patients were randomized in two arms each consisting of 20 patients. Patients in both arms received concurrent chemoradiation (cisplatin 40mg/m(2) weekly; 50Gy/25 fractions). Patients were treated with 3D conformal radiotherapy in one arm and with IMRT in another arm. After external beam radiotherapy, all patients received brachytherapy (21Gy/3 fractions at weekly interval). For dosimetric comparison, both kinds of the plans were done for all the patients. All patients were assessed throughout and until 90 days after completion of treatment for acute gastrointestinal, genitourinary and hematologic toxicities.
RESULTS: Both plans achieved adequate planning target volume coverage, while mean conformity index was found significantly better in IMRT plans (P-value=0.001). D35 (dose to 35% volume) and D50 for bladder was reduced by 14.62 and 32.57% and for rectum by 23.82 and 43.68% in IMRT. For IMRT, V45 (volume receiving 45Gy) of bowel were found significantly lesser (P-value=0.0001), non-tumour integral dose was found significantly higher (P-value=0.0240) and V20 of bone marrow was found significantly reduced (P-value=0.019) in comparison to that in 3D conformal radiotherapy. Significant reduction of grade 2 or more (20 vs 45%; P-value=0.058) and grade≥3 (5 vs 15%, P-value=0.004) acute genitourinary toxicity and grade 2 or more (20 vs 45%, P-value=0.003) and grade 3 or more (5 vs. 20%, P-value=0.004) acute gastrointestinal toxicity while no significant difference for grade 2 and 3 or more haematological toxicity was noted in patients treated with IMRT compared to 3D conformal radiotherapy.
CONCLUSION: IMRT provide a good alternative for treatment of cervix carcinoma with lower acute gastrointestinal and acute genitourinary toxicity with similar target coverage compared to 3D conformal radiotherapy.
Copyright © 2016 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  Carcinoma cervix; Carcinome du col de l’utérus; Intensity-modulated radiotherapy; Radiothérapie conformation tridimensionnelle; Radiothérapie conformationnelle avec modulation d’intensité; Three-dimensional conformal radiotherapy; Toxicity; Toxicité aiguë

Mesh:

Substances:

Year:  2016        PMID: 27368915     DOI: 10.1016/j.canrad.2016.05.011

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  19 in total

1.  External validation of a combined PET and MRI radiomics model for prediction of recurrence in cervical cancer patients treated with chemoradiotherapy.

Authors:  François Lucia; Dimitris Visvikis; Martin Vallières; Marie-Charlotte Desseroit; Omar Miranda; Philippe Robin; Pietro Andrea Bonaffini; Joanne Alfieri; Ingrid Masson; Augustin Mervoyer; Caroline Reinhold; Olivier Pradier; Mathieu Hatt; Ulrike Schick
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-12-07       Impact factor: 9.236

2.  Prediction of outcome using pretreatment 18F-FDG PET/CT and MRI radiomics in locally advanced cervical cancer treated with chemoradiotherapy.

Authors:  François Lucia; Dimitris Visvikis; Marie-Charlotte Desseroit; Omar Miranda; Jean-Pierre Malhaire; Philippe Robin; Olivier Pradier; Mathieu Hatt; Ulrike Schick
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-12-09       Impact factor: 9.236

3.  Radiation-induced acute toxicities after image-guided intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for patients with spinal metastases (IRON-1 trial) : First results of a randomized controlled trial.

Authors:  Tanja Sprave; Vivek Verma; Robert Förster; Ingmar Schlampp; Thomas Bruckner; Tilman Bostel; Stefan Ezechiel Welte; Eric Tonndorf-Martini; Rami El Shafie; Nils Henrik Nicolay; Jürgen Debus; Harald Rief
Journal:  Strahlenther Onkol       Date:  2018-07-05       Impact factor: 3.621

Review 4.  Radiotherapy for cervical cancer: Chilean consensus of the Society of Radiation Oncology.

Authors:  Felipe Carvajal; Claudia Carvajal; Tomás Merino; Verónica López; Javier Retamales; Evelyn San Martín; Freddy Alarcón; Mónica Cuevas; Francisca Barahona; Ignacio Véliz; Juvenal A Ríos; Sergio Becerra
Journal:  Rep Pract Oncol Radiother       Date:  2021-04-14

5.  Early morbidity and dose-volume effects in definitive radiochemotherapy for locally advanced cervical cancer: a prospective cohort study covering modern treatment techniques.

Authors:  Yvette Seppenwoolde; Katarina Majercakova; Martin Buschmann; Elke Dörr; Alina E Sturdza; Maximilian P Schmid; Richard Pötter; Dietmar Georg
Journal:  Strahlenther Onkol       Date:  2021-04-30       Impact factor: 3.621

6.  Radiation Therapy for Cervical Cancer: Executive Summary of an ASTRO Clinical Practice Guideline.

Authors:  Junzo Chino; Christina M Annunziata; Sushil Beriwal; Lisa Bradfield; Beth A Erickson; Emma C Fields; KathrynJane Fitch; Matthew M Harkenrider; Christine H Holschneider; Mitchell Kamrava; Eric Leung; Lilie L Lin; Jyoti S Mayadev; Marc Morcos; Chika Nwachukwu; Daniel Petereit; Akila N Viswanathan
Journal:  Pract Radiat Oncol       Date:  2020-05-18

Review 7.  Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers.

Authors:  Theresa A Lawrie; John T Green; Mark Beresford; Linda Wedlake; Sorrel Burden; Susan E Davidson; Simon Lal; Caroline C Henson; H Jervoise N Andreyev
Journal:  Cochrane Database Syst Rev       Date:  2018-01-23

Review 8.  The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies.

Authors:  Richard Pötter; Kari Tanderup; Christian Kirisits; Astrid de Leeuw; Kathrin Kirchheiner; Remi Nout; Li Tee Tan; Christine Haie-Meder; Umesh Mahantshetty; Barbara Segedin; Peter Hoskin; Kjersti Bruheim; Bhavana Rai; Fleur Huang; Erik Van Limbergen; Max Schmid; Nicole Nesvacil; Alina Sturdza; Lars Fokdal; Nina Boje Kibsgaard Jensen; Dietmar Georg; Marianne Assenholt; Yvette Seppenwoolde; Christel Nomden; Israel Fortin; Supriya Chopra; Uulke van der Heide; Tamara Rumpold; Jacob Christian Lindegaard; Ina Jürgenliemk-Schulz
Journal:  Clin Transl Radiat Oncol       Date:  2018-01-11

9.  Early Clinical Outcomes, Patterns of Failure, and Acute Haematologic Toxicity of Image-Guided Volumetric Modulated Arc Therapy (IG-VMAT) in the Definitive Treatment of Locally Advanced Carcinoma Cervix.

Authors:  Irfan Ahmad; Kundan Singh Chufal; Irfan Bashir; Chandi Prasad Bhatt; Ram Bajpai; Lalit Sharma; Sandeep Rathour
Journal:  Clin Med Insights Oncol       Date:  2018-06-27

10.  Intensity-modulated radiation therapy for definitive treatment of cervical cancer: a meta-analysis.

Authors:  Yanzhu Lin; Kai Chen; Zhiyuan Lu; Lei Zhao; Yalan Tao; Yi Ouyang; Xinping Cao
Journal:  Radiat Oncol       Date:  2018-09-14       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.